Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD

References

• VogelmeierCF, CrinerGJ, MartinezFJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195:557–582. doi:10.1164/rccm.201701-0218PP28128970
   PubMed Web of Science ®Google Scholar
• VestboJ, HurdSS, AgustiAG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–365. doi:10.1164/rccm.201204-0596PP22878278
   PubMed Web of Science ®Google Scholar
• LakshmiSP, ReddyAT, ReddyRC. Emerging pharmaceutical therapies for COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2141–2156. doi:10.2147/COPD.S12141628790817
   PubMed Web of Science ®Google Scholar
• AdcockIM, ItoK. Glucocorticoid pathways in chronic obstructive pulmonary disease therapy. Proc Am Thorac Soc. 2005;2:313–319. discussion 40-1. doi:10.1513/pats.200504-035SR.16267355
   PubMedGoogle Scholar
• BurgePS, CalverleyPM, JonesPW, SpencerS, AndersonJA, MaslenTK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–1303. doi:10.1136/bmj.320.7245.129710807619
   PubMed Web of Science ®Google Scholar
• CalverleyP, PauwelsR, VestboJ, et al. long-acting beta2 agonists study g. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449–456. doi:10.1016/S0140-6736(03)12459-212583942
   PubMed Web of Science ®Google Scholar
• BarnesPJ, AdcockIM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373:1905–1917. doi:10.1016/S0140-6736(09)60326-319482216
   PubMed Web of Science ®Google Scholar
• GrossKL, LuNZ, CidlowskiJA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol. 2009;300:7–16. doi:10.1016/j.mce.2008.10.00119000736
   PubMed Web of Science ®Google Scholar
• MarwickJA, CaramoriG, StevensonCS, et al. Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med. 2009;179:542–548. doi:10.1164/rccm.200810-1570OC19164702
   PubMed Web of Science ®Google Scholar
• KawamatawongT. Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. J Thorac Dis. 2017;9:1144–1154. doi:10.21037/jtd28523172
   PubMed Web of Science ®Google Scholar
• WedzichaJA, RabeKF, MartinezFJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013;143:1302–1311. doi:10.1378/chest.12-148923117188
   PubMed Web of Science ®Google Scholar
• SinghD, AgustiA, AnzuetoA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53. doi:10.1183/13993003.00164-2019.
   Web of Science ®Google Scholar
• BuenestadoA, Grassin-DelyleS, GuitardF, et al. Roflumilast inhibits the release of chemokines and TNF-alpha from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol. 2012;165:1877–1890. doi:10.1111/j.1476-5381.2011.01667.x21913898
   PubMed Web of Science ®Google Scholar
• GrootendorstDC, GauwSA, VerhooselRM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62:1081–1087. doi:10.1136/thx.2006.07593717573446
   PubMed Web of Science ®Google Scholar
• MilaraJ, LluchJ, AlmudeverP, FreireJ, XiaozhongQ, CortijoJ. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014;134:314–322. doi:10.1016/j.jaci.2014.02.00124636089
   PubMed Web of Science ®Google Scholar
• RennardSI, CalverleyPM, GoehringUM, BredenbrokerD, MartinezFJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast–the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18. doi:10.1186/1465-9921-12-1821272339
   PubMed Web of Science ®Google Scholar
• ReddyAT, LakshmiSP, BannoA, ReddyRC. Role of GPx3 in PPARgamma-induced protection against COPD-associated oxidative stress. Free Radic Biol Med. 2018;126:350–357. doi:10.1016/j.freeradbiomed.2018.08.01430118830
   PubMed Web of Science ®Google Scholar
• LakshmiSP, ReddyAT, BannoA, ReddyRC. Airway epithelial cell peroxisome proliferator-activated receptor gamma regulates inflammation and mucin expression in allergic airway disease. J Immunol. 2018;201:1775–1783. doi:10.4049/jimmunol.180064930061200
   PubMed Web of Science ®Google Scholar
• LakshmiSP, ReddyAT, ReddyRC. Transforming growth factor beta suppresses peroxisome proliferator-activated receptor gamma expression via both SMAD binding and novel TGF-beta inhibitory elements. Biochem J. 2017;474:1531–1546. doi:10.1042/BCJ2016094328100650
   PubMed Web of Science ®Google Scholar
• GovindanMV. Recruitment of cAMP-response element-binding protein and histone deacetylase has opposite effects on glucocorticoid receptor gene transcription. J Biol Chem. 2010;285:4489–4510. doi:10.1074/jbc.M109.07272820018896
   PubMed Web of Science ®Google Scholar
• PenuelasI, EncioIJ, Lopez-MoratallaN, SantiagoE. cAMP activates transcription of the human glucocorticoid receptor gene promoter. J Steroid Biochem Mol Biol. 1998;67:89–94. doi:10.1016/S0960-0760(98)00097-19877208
   PubMed Web of Science ®Google Scholar
• BarnesPJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131:636–645. doi:10.1016/j.jaci.2012.12.156423360759
   PubMed Web of Science ®Google Scholar
• WedzichaJA, CalverleyPM, RabeKF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:81–90. doi:10.2147/COPD.S8984926792988
   PubMed Web of Science ®Google Scholar
• BourbeauJ, ChristodoulopoulosP, MaltaisF, YamauchiY, OlivensteinR, HamidQ. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax. 2007;62:938–943. doi:10.1136/thx.2006.07106817557771
   PubMed Web of Science ®Google Scholar
• CulpittSV, MaziakW, LoukidisS, NightingaleJA, MatthewsJL, BarnesPJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1635–1639. doi:10.1164/ajrccm.160.5.981105810556133
   PubMed Web of Science ®Google Scholar
• KeatingsVM, JatakanonA, WorsdellYM, BarnesPJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997;155:542–548. doi:10.1164/ajrccm.155.2.90321929032192
   PubMed Web of Science ®Google Scholar
• MilaraJ, MorellA, BallesterB, et al. Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist. Respir Res. 2015;16:12. doi:10.1186/s12931-015-0179-525652132
   PubMed Web of Science ®Google Scholar
• KornSH, ThunnissenFB, WesselingGJ, ArendsJW, WoutersEF. Glucocorticoid receptor mRNA levels in bronchial epithelial cells of patients with COPD: influence of glucocorticoids. Respir Med. 1998;92:1102–1109. doi:10.1016/S0954-6111(98)90402-49926163
   PubMed Web of Science ®Google Scholar
• DongY, PoellingerL, GustafssonJA, OkretS. Regulation of glucocorticoid receptor expression: evidence for transcriptional and posttranslational mechanisms. Mol Endocrinol. 1988;2:1256–1264. doi:10.1210/mend-2-12-12563216865
   PubMedGoogle Scholar
• RosewiczS, McDonaldAR, MadduxBA, GoldfineID, MiesfeldRL, LogsdonCD. Mechanism of glucocorticoid receptor down-regulation by glucocorticoids. J Biol Chem. 1988;263:2581–2584.3343225
   PubMed Web of Science ®Google Scholar
• CalverleyPM, Sanchez-TorilF, McIvorA, TeichmannP, BredenbroekerD, FabbriLM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:154–161. doi:10.1164/rccm.200610-1563OC17463412
   PubMed Web of Science ®Google Scholar
• FabbriLM, CalverleyPM, Izquierdo-AlonsoJL, et al. M, groups Ms. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374:695–703. doi:10.1016/S0140-6736(09)61252-619716961
   PubMed Web of Science ®Google Scholar
• GiembyczMA. Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:326–333. discussion 40-1. doi:10.1513/pats.200504-041SR.16267357
   PubMedGoogle Scholar
• HakonarsonH, BjornsdottirUS, HalapiE, et al. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci U S A. 2005;102:14789–14794. doi:10.1073/pnas.040990410216203992
   PubMed Web of Science ®Google Scholar
• PujolsL, MullolJ, PerezM, et al. Expression of the human glucocorticoid receptor alpha and beta isoforms in human respiratory epithelial cells and their regulation by dexamethasone. Am J Respir Cell Mol Biol. 2001;24:49–57. doi:10.1165/ajrcmb.24.1.402411152650
   PubMed Web of Science ®Google Scholar
• LeaS, MetrykaA, LiJ, et al. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients. Cytokine. 2019;123:154739. doi:10.1016/j.cyto.2019.15473931319374
   PubMed Web of Science ®Google Scholar
• GongS, ChenY, MengF, et al. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis. Cell Prolif. 2018;51:e12474. doi:10.1111/cpr.1247430069985
   PubMed Web of Science ®Google Scholar
• GongS, ChenY, MengF, ZhangY, WuH, WuF. Roflumilast restores cAMP/PKA/CREB signaling axis for FtMt-mediated tumor inhibition of ovarian cancer. Oncotarget. 2017;8:112341–112353. doi:10.18632/oncotarget.2286629348829
   PubMedGoogle Scholar
• RolewskaP, SimmA, SilberRE, BartlingB. Reduced expression level of the cyclic adenosine monophosphate response element-binding protein contributes to lung aging. Am J Respir Cell Mol Biol. 2014;50:201–211. doi:10.1165/rcmb.2013-0057OC23991634
   PubMed Web of Science ®Google Scholar
• ItoK, BarnesPJ. COPD as a disease of accelerated lung aging. Chest. 2009;135:173–180. doi:10.1378/chest.08-141919136405
   PubMed Web of Science ®Google Scholar
• MacNeeW. Is chronic obstructive pulmonary disease an accelerated aging disease? Ann Am Thorac Soc. 2016;13(Suppl 5):S429–S37. doi:10.1513/AnnalsATS.201602-124AW28005421
   PubMed Web of Science ®Google Scholar
• RodriguezJM, Monsalves-AlvarezM, HenriquezS, LlanosMN, TroncosoR. Glucocorticoid resistance in chronic diseases. Steroids. 2016;115:182–192. doi:10.1016/j.steroids.2016.09.01027643454
   PubMed Web of Science ®Google Scholar